This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Latest News
-
7th September 2023
ARECOR ANNOUNCES POSITIVE PRE-IND MEETING WITH FDA FOR NOVEL READY-TO-USE MEDICINE AT307 LICENSED TO HIKMA
-
4th September 2023
TETRIS PHARMA ANNOUNCES COMMERCIALISATION AGREEMENT WITH GOODLIFE
-
17th August 2023
ARECOR TO COLLABORATE WITH TOP 10 GLOBAL PHARMACEUTICAL COMPANY
News
-
13/12/2018
Arecor to attend the 37th annual J.P. Morgan healthcare conference
-
29/10/2018
Press Release – Arecor successfully defends a key European patent in opposition proceedings on the subject of mitigation of aggregation of therapeutic proteins during storage
-
15/10/2018
Press release – Arecor joins ELITE Investor Roadshow to China
-
10/09/2018
Press Release – Arecor secures £6m investment for the clinical development of its diabetes speciality pharma portfolio
-
08/08/2018
Press Release – Arecor to give a short course and present at the Bioprocessing Summit, 13th-17th August 2018, Sheraton Boston, Boston, MA, USA
-
02/07/2018
Patent portfolio update – Arecor successfully defends a key European polysaccharide vaccine patent in its opposition proceedings
-
21/06/2018
Press release – Arecor announces Superfast Insulin data presentations at the American Diabetes Association 78th Scientific Sessions
-
19/06/2018
Press release – US$1.3 million grant awarded to Arecor & Manchester Institute of Biotechnology
-
10/05/2018
Arecor to present at the World Congress’ Biologics Formulation and Drug Delivery Technologies Summit 2018 in Boston, MA, USA
-
10/01/2018
Arecor Ltd is pleased to announce the launch of its new website at: www.arecor.com
-
08/01/2018
European patent for Arecor’s proprietary technology enabling highly concentrated biotherapeutics
-
04/01/2018
Arecor and JDRF announce successful pre-clinical development of stable rapid-acting, ultra-concentrated insulin for the significantly enhanced treatment of type 1 diabetes